Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05754450 · ClinicalTrials.gov registry record · Phase 3
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II
A Phase 3 study of Leukocyte Adhesion Deficiency, sponsored by AUG Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT05754450: Recruiting Phase 3 study of Leukocyte Adhesion Deficiency, sponsored by AUG Therapeutics.
NCT05754450 is a Phase 3 study of Leukocyte Adhesion Deficiency that is actively recruiting participants, run by AUG Therapeutics. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05754450, a Phase 3 study of Leukocyte Adhesion Deficiency, is actively recruiting participants, sponsored by AUG Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
Conditions Studied
Interventions
- DRUG AVTX-803
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05754450
The ClinicalTrials.gov registry entry for NCT05754450 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AUG Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukocyte Adhesion Deficiency appearing as the primary indexed condition, and to 1 intervention - of which AVTX-803 is the first listed.
NCT05754450 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05754450 about?
NCT05754450 is a clinical study titled "An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II". The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
What is the current status of trial NCT05754450?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2023-04-10. Estimated completion is 2024-12-31.
What conditions does trial NCT05754450 study?
This clinical trial studies the following conditions: Leukocyte Adhesion Deficiency.
What interventions are being tested in trial NCT05754450?
The interventions under investigation include: AVTX-803 (DRUG).
Who is sponsoring clinical trial NCT05754450?
This trial is sponsored by AUG Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05754450 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukocyte Adhesion Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.